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Abstract
Background
Despite increased antiretroviral therapy (ART) coverage and the raised CD4 threshold for
starting ART, opportunistic infections (OIs) are still one of the leading causes of death in
sub-Saharan Africa. There are few studies from resource-limited settings on long-term
reporting of OIs other than tuberculosis.
Methods
Patients starting ART between April 2004 and April 2005 were enrolled and followed-up for
10 years in Kampala, Uganda. We report incidences, patterns and risk factors using Cox
proportional hazards models of OIs among all patients and among patients with CD4 cell
counts >200 cells/μL.
Results
Of the 559 patients starting ART, 164 patients developed a total of 241 OIs during 10 years
of follow-up. The overall incidence was highest for oral candidiasis (25.4, 95% confidence
interval (CI): 20.5–31.6 per 1000 person-years of follow-up), followed by tuberculosis (15.3,
95% CI: 11.7–20.1), herpes zoster (12.3, 95% CI: 9.1–16.6) and cryptococcal meningitis
(3.0, 95% CI: 1.7–5.5). Incidence rates for all OIs were highest in the first year after ART ini-
tiation and decreased with the increase of the current CD4 cell count. Factors independently
associated with development of OIs were baseline nevirapine-based regimens, time-varying
higher viral load, time-varying lower CD4 cell count and time-varying lower hemoglobin. In
patients developing OIs at a current CD4 cell count >200 cells/μL, factors independently
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associated with OI development were time-varying increase in viral load and time-varying
decrease in hemoglobin, whereas a baseline CD4 cell count <50 cells/μL was protective.
Conclusion
We report high early incidences of OIs, decreasing with increasing CD4 cell count and time
spent on ART. Ongoing HIV replication and anemia were strong predictors for OI develop-
ment independent of the CD4 cell count. Our findings support the recommendation for early
initiation of ART and suggest close monitoring for OIs among patients recently started on
ART, with low CD4 cell count, high viral load and anemia.
Introduction
Chronic HIV-infection leads to immunosuppression through a progressive depletion of CD4
cells [1] and impairment of cellular immunity [2]. This leads to increased susceptibility to
opportunistic infections (OIs) such as tuberculosis or Pneumocystis jirovecii pneumonia
(PJP), which cause morbidity and mortality in the natural course of HIV disease [3, 4]. The
introduction of antiretroviral therapy (ART), particularly combination antiretroviral treat-
ment, has been pivotal in decreasing morbidity and mortality caused by HIV infection [5–9].
In resource-rich countries, life expectancy of newly infected people living with HIV (PLHIV)
started on ART has almost reached the lifespan of the general population [10, 11].
More recently, some resource-limited countries have also shown a strong reduction in
HIV-related morbidity and mortality with a 36% decrease of AIDS-related deaths in Eastern
and Southern Africa, the region with a highest burden of HIV/AIDS globally, with 19 million
PLHIV in 2015 [12, 13]. In Uganda, ART coverage reached 57% in 2015 [14] and HIV-related
deaths declined from 120’000 in 1998 to 28’000 in 2015 [15, 16]. However, HIV-related mortal-
ity is still one of the leading causes of death in Uganda and sub-Saharan Africa, and is mainly
due to OIs [17]. Despite increased ART coverage and the increase in CD4 threshold for start-
ing ART, many PLHIV in this setting access clinical care at a late stage of the disease, when
advanced immunosuppression considerably increases the risk of OIs [18–20]. In a meta-analy-
sis of 27 countries in sub-Saharan Africa, no change of CD4 cell counts at ART initiation was
observed between 2002 and 2013 [21]. The most common OIs occurring in sub-Saharan Africa
are oral candidiasis, tuberculosis and herpes zoster, both in ART-naïve patients, as well as in
the first year after ART initiation [22].
However, recent publications show that even patients with good immune reconstitution are
still at risk of acquiring OIs [23, 24]. Most prevalent factors associated with the occurrence of
OIs while on ART include malnutrition, younger age and low CD4 cell count at ART start
[25–31]. Remarkably, even years after starting ART, OIs may occur. However, long-term
reporting on OIs while on ART other than tuberculosis is scanty especially from sub-Saharan
Africa [25]. Here we provide a retrospective analysis of a 10-year cohort in Uganda and report
incidences and risk factors for OIs during ART.
Methods
Study setting and population
The Infectious Diseases Institute (IDI) is an HIV center of excellence [32] with a large clinic in
Kampala, Uganda, with over 8000 PLHIV in care. In 2004, when IDI started to provide free
Opportunistic infections among people living with HIV on antiretroviral therapy in Uganda
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ART through the Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM) and United
States President’s Emergency Plan for AIDS Relief (PEPFAR), a research cohort of patients
starting ART was established, whose study procedures have been described in detail elsewhere
[33]. In summary, 559 ART-naïve patients who were 18 years or older and who were willing to
participate in the study were consecutively enrolled and initiated on ART between April 2004
and April 2005, and were followed-up for 10 years. The patients were eligible for ART accord-
ing to the World Health Organization (WHO) and the 2003 Ugandan National Guidelines
(CD4 cell count <200 cells/μL or WHO stage IV regardless of the CD4 cell count). First-line
regimens included stavudine or zidovudine plus lamivudine plus either nevirapine or efavirenz
[15, 34]. Regimens were switched in case of grade 3 or 4 toxicity with a single drug change
according to the AIDS Clinical Trials Group (ACTG) classification. After the 2008 Ministry of
Health recommendation, stavudine was replaced in all patients by either zidovudine or tenofo-
vir, regardless of side effects. Patients with 2 consecutive viral loads >1000 cells/μL were con-
sidered eligible for protease inhibitor-based second-line regimens (ritonavir-boosted lopinavir
or ritonavir-boosted atazanavir since 2013). However, if viremia was low, the present first-line
regimen was maintained, and additional adherence counseling was performed. Switches also
occurred when tuberculosis was diagnosed (substitution of nevirapine with efavirenz) or in
women found to or planning to become pregnant (replacement of efavirenz with nevirapine
up to 2012) [35]. All patients received trimethoprim-sulfamethoxazole prophylaxis regardless
of the CD4 cell count, and dapsone was used as an alternative in case of intolerance. Flucona-
zole primary prophylaxis was not routinely provided for patients with low CD4 cell counts, as
no clinic-wide protocol or WHO guidelines for patients with low CD4 cell counts existed at
that time. Patients with a positive serum cryptococcal antigen (CRAG) should have received
Fluconazole to prevent meningitis. However, some patients with a positive CRAG were
untraceable or died before results were available. Isoniazid preventive therapy was not
provided.
At baseline, patients were enrolled into the cohort and initiated on ART. During the three-
monthly follow-up visits as well as at baseline, information on demographic characteristics,
vital parameters and medical history was assessed, and a clinical examination was performed.
Symptoms were screened through a standardized checklist (supporting information, S1
Table). At enrollment, every patient was tested for cryptococcal antigenemia (latex agglutina-
tion method) irrespectively of the presence of symptoms or CD4 cell count and a chest x-ray
was performed regardless of the symptoms. The data was collected through a standardized
questionnaire and included detailed information on presence and duration of symptoms,
opportunistic infections and clinical findings. Laboratory tests included a full blood cell count,
liver and renal function tests, CD4 cell counts (FACSCount, Becton Dickinson, and more
recently by FACSCalibur, Becton Dickinson) and viral load measurements (Amplicor HIV-1
Monitor PCR Test version 1.5, Roche Diagnostics, and more recently by COBAS AmpliPrep/
COBAS TaqMan HIV-1 Test version 2.0, Roche Diagnostics) and were performed at baseline
and every 6 months. Outcomes of this cohort study including CD4 cell counts, viral loads and
ART switches over the ten years have been described previously [35].
Assessment of opportunistic infections and data validation
Relevant OIs included non-AIDS-defining OIs, as well as AIDS-defining OIs, AIDS malignan-
cies and HIV-related syndromic diagnoses. OI as a general term was implemented in accor-
dance with previous studies to harmonize these differences [36]. The following OIs and HIV-
related conditions were systematically recorded over the 480-week period of the cohort study:
oropharyngeal and esophageal candidiasis, tuberculosis, PJP, toxoplasmosis of the brain,
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cryptococcal meningitis, Kaposi’s sarcoma, lymphoma, cervical cancer, herpes zoster, HIV
encephalopathy, pulmonary aspergillosis and unexplained chronic diarrhea. Pulmonary tuber-
culosis was diagnosed through a combination of microscopic examination for acid fast bacteria
(AFB) of the sputum, chest x-ray (interpreted by the clinician) and clinical judgement (pres-
ence of symptoms, successful response to standard antituberculosis therapy). Xpert MTB/RIF
was introduced in 2011. Culturing methods were not available. The diagnosis of extrapulmon-
ary tuberculosis was confirmed by fine needle aspiration and microscopic examination for
AFB in lymph nodes, abdominal ultrasounds and cerebrospinal fluid analysis. Cryptococcal
meningitis was diagnosed through CRAG testing (latex agglutination method and lateral flow
assay since 2007) and microscopic and cytological examination of the cerebrospinal fluid. PJP
was diagnosed through clinical judgement and chest x-ray. Computed tomography (CT) scan
was made available when toxoplasmosis of the brain was suspected. The diagnoses of Kaposi’s
sarcoma, lymphoma and cervical cancer were confirmed through biopsy and histology. Oral
and esophageal candidiasis as well as herpes zoster were diagnosed by clinical presentation
only. A detailed description of the diagnostic approaches of all opportunistic infections can be
found in the supporting information (S2 Table). The collected data were entered initially into
an Oracle software database (version 9.0) and later into the Integrated Clinic Enterprise Appli-
cation (ICEA) database, an in-house built software that provides good quality data collection,
with minimal missing or incorrect information [37]. The data on OIs for this article was
obtained from the ICEA database and cross-checked with the hand-written medical chart.
Statistical analysis
Baseline characteristics were described using medians for continuous variables and proportions
for categorical variables. Patients that were lost to therapy were censored at their last visit when
they were prescribed ART. OIs that were causes of death were included into the analysis. We
excluded OIs that were already symptomatic before or at the enrollment into the cohort. Inci-
dence rates for any OI and for selected common OIs for each period were calculated yearly until
year 10 after initiation of ART. The incidence rates of any OI and selected common OIs were also
calculated within the current (or latest) CD4 cell count strata (defined as<100, 100–199, 200–349
and�350 cells/μL) they occurred in. As CD4 cell counts were performed every 6 months, current
was defined as within the last 6 months. We calculated the cumulative probability of developing a
first new OI using Kaplan-Meier estimates stratified by baseline CD4 cell count (<50, 50–100,
and>100 cells/μL) and compared them using log-rank test. Risk factors for first OI occurrences
were assessed using univariate and multivariate Cox proportional hazards models. Variables
included were: age, gender, baseline WHO stage, baseline ART regimen (nevirapine-based or efa-
virenz-based), current regimen (first- or second-line), baseline and time-varying body mass index
(BMI), CD4 cell count, viral load and hemoglobin. We used propensity scores methods to predict
probability of regimen allocation (nevirapine-based or efavirenz-based regimen) at ART initia-
tion. Variables with a p value<0.2 and those of clinical significance in the univariate analysis
were included in the multivariate model. A second analysis, using the same model and including
the same variables, was performed to investigate risk factors for OIs occurring at a CD4 cell count
>200 cells/μL. Patients were included in the analysis on the date of their first recorded CD4 cell
count>200 cells/μL and censored when the CD4 cell count dropped below 200 cells/μL. All anal-
yses were conducted using Stata software, version 13 (StataCorp, College Station, TX, USA).
Ethical statement
The study was approved by the Makerere University Faculty of Medicine Research and Ethics
Committee (Approval number: 016–2004) and the Uganda National Council for Science and
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Technology (Approval number: MV 853). Patients provided written consent to participate in
the study.
Results
Baseline characteristics
Five hundred fifty-nine patients were enrolled, contributing 2759.2 person-years of follow-up
(PYFU) to the analysis. One hundred and twenty-seven (22.7%) died, 23 (4.1%) were trans-
ferred to other health centers, 24 (4.3%) withdrew consent, 31 (5.5%) were lost to therapy and
354 (63.3%) completed 480 weeks of follow up. Baseline characteristics are shown in Table 1.
Three hundred and eighty-six (69.0%) were female and the median age of the 559 patients was
35 (interquartile range (IQR), 30–41). The median CD4 cell count of all patients at ART initia-
tion was 98 cells/μL (IQR, 21–163 cells/μL) and 497 (88.9%) patients were classified as WHO
stage III or IV; the median viral load at ART initiation was 5.4 log10 copies/mL (IQR, 5.1–5.8
log10 copies/mL). ART regimen at baseline included nevirapine-based regimens, administered
to 414 (74.1%) patients and efavirenz-based regimens, administered to 145 (25.9%) patients.
Of the 31 patients that were lost to therapy, 18 (58.1%) were female, and the median CD4 cell
count at baseline was 140 cells/μL (IQR, 21–179 cells/μL).
Patterns of OIs
During the entire follow-up period, a total of 241 new OIs occurred in 164 patients, of which
109/164 (66.5%) had one OI, 40 (24.4%) had two and 15 (9.1%) patients had three or more
OIs. One hundred and seventy-two (71.4%) OIs occurred in the first year after ART initiation
whereas 27/241 (11.2%) OIs occurred in the second year. The most common OI was oropha-
ryngeal candidiasis (n = 105/241, 43.6%), followed by tuberculosis (n = 52, 21.6%), herpes zos-
ter (n = 48, 19.9%) and cryptococcal meningitis (n = 11, 4.6%). In the first year after ART start,
oral candidiasis was the most common OI (n = 84/172, 48.8%), followed by herpes zoster
Table 1. Baseline characteristics.
Characteristics (All Patients: N = 559)
Age (years); median (IQR) 35 (30–41)
Female gender; n (%) 386 (69.0)
BMI (kg/m2); median (IQR) 20 (18–22)
WHO Stage
I/II; n (%) 62 (11.1)
III/IV; n (%) 497 (88.9)
CD4 cell count (cells/μl)
Median (IQR) 98 (21–163)
<50; n (%) 198 (35.8)
50–100; n (%) 94 (17.0)
>100; n (%) 261 (47.2)
Viral load (log10 copies/mL); median (IQR) 5.4 (5.1–5.8)
Hemoglobin level (g/dl); median (IQR) 11.5 (10.3–12.9)
ART regimen
Nevirapine-based; n (%) 414 (74.1)
Efavirenz-based; n (%) 145 (25.9)
ART: antiretroviral therapy; BMI: body mass Index; IQR: interquartile range; WHO: World Health Organization
https://doi.org/10.1371/journal.pone.0206796.t001
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(n = 33, 19.2%) and tuberculosis (n = 30, 17.4%). After the first year, tuberculosis remained the
most common OI (n = 22/69, 31.9%), followed by oral candidiasis (n = 21, 30.4%) and herpes
zoster (n = 15, 21.7%). All 11 cases of cryptococcal meningitis appeared in the first year after
ART start. A list of all OIs diagnosed can be found in the supporting information (S3 Table).
The median CD4 cell count at any OI diagnosis was 121 cells/μL, (IQR, 24–268 cells/μL),
with a median of 14 cells/μL (IQR, 4–90 cells/μL) in patients with cryptococcal meningitis, 102
cells/μL (IQR, 8–189 cells/μL) for oral candidiasis, 140 cells/μL (IQR, 45–253 cells/μL) for
tuberculosis and 268 cells/μL (IQR, 128–324 cells/μL) in patients diagnosed with herpes zoster.
Incidences of OIs and relation to CD4 cell count
The overall incidence rate of new OIs over the 480-week period was 59.4 (95% confidence
interval (CI) 51.0–69.3) per 1000 PYFU. The incidence rate was highest in the first year after
ART start with 333.0 (95% CI, 281.2–394.5) per 1000 PYFU, followed by 36.8 (95% CI, 20.9–
64.9) per 1000 PYFU in the second year. After the second year, incidence rates stabilized at a
lower level (supporting information, S4 Table).
The overall incidence was highest for oral candidiasis with an incidence rate of 25.4 (95%
CI, 20.5–31.6) per 1000 PYFU, followed by tuberculosis [15.3 (95% CI, 11.7–20.1)], herpes zos-
ter [12.3 (95% CI: 9.1–16.6)] and cryptococcal meningitis [3.0 (95% CI, 1.7–5.5)]. Yearly inci-
dence rates of the most frequent OIs are shown in Fig 1.
Fig 1. Yearly incidence rates of the 4 most frequent opportunistic infections in a cohort of patients on ART followed up for 10 years. ART:
antiretroviral therapy; OIs: opportunistic infections.
https://doi.org/10.1371/journal.pone.0206796.g001
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Incidence rates of any OI per current CD4 cell count were lower for patients with a CD4
cell count of�350 cells/μL (9.8 per 1000 PYFU (95% CI, 6.4–14.9)) to compared to patients
with a CD4 cell count of<100 cells/μL (1507.5 per 1000 PYFU (95% CI, 1190.7–1908.7)).
Number of events and incidence rates of the individual OIs per current CD4 cell strata are
shown in Table 2.
The cumulative probability for the development of an OI during the 10 years of follow up
according to the baseline CD4 count is depicted in Fig 2. This differed significantly among the
CD4 cell count strata at ART initiation, with the highest probability (0.41, 95% CI: 0.34–0.49)
of an OI among patients with a baseline CD4 cell count <50 cells/μL as compared to patients
with a baseline CD4 cell count of 50–100 cells/μL (0.31, 95% CI: 0.22–0.43) and>100 cells/μL
(0.29, 95% CI: 0.23–0.35) (P = 0.010).
Of the 164 patients that developed any new OI, 45 (27.4%) died during the follow-up. The
incident new OI was the cause of death within 16/164 (9.8%) patients while the remaining 29/
45 deaths were the result of another prevalent OI (at time of ART start) or a non-HIV-related
condition. Incidence of mortality due to the incident OI was 3.4 per 1000 PYFU (95% CI: 2.7–
7.1). Causes of death due to the incident OI are shown in the supporting information (S5
Table).
Risk factors
Risk factors for OI development are shown in Table 3. In the multivariate model, time-varying
higher viral load (HR: 2.42 per 1 log increase; 95% CI: 2.05–2.85; P<0.001) was associated with
OI development. Patients with higher time-varying CD4 cell count (HR: 0.90 per 50 cells/μL
increase; 95% CI: 0.81–1.00; P = 0.050), higher time-varying hemoglobin level (HR: 0.90 per 1
g/dL increase; 95% CI: 0.81–1.00; P = 0.045) and baseline efavirenz-based regimen as com-
pared to nevirapine (HR: 0.56; 95% CI: 0.37–0.83; P = 0.004) were less likely to develop an OI.
OIs at a current CD4 cell count >200 cell/μL
A total of 90 OIs in 56 patients occurred at current CD4 cell count>200 cell/μL. The most
common OIs were herpes zoster (n = 30, 33.3%), oral candidiasis (n = 28, 31.1%) and tubercu-
losis (n = 23, 25.6%).
Table 2. Incidence rates (per 1000 PYFU) of selected most common OIs stratified by current CD4 cell count in a cohort of patients on ART followed up for 10
years.
CD4 cell stratum (cells/μL)
<100 100–199 200–349 �350
Number of events 69 38 34 22
Incidence rate
(95% CI)
1507.5
(1190.7–1908.7)
359.9
(261.9–494.6)
95.0
(67.9.5–133.0)
9.8
(6.4–14.9)
Oral candidiasis 964.2
(707.3–1314.5)
199.3
(131.3–302.8)
23.0
(11.9–44.1)
3.7
(2.0–6.9)
Tuberculosis 386.3
(246.4–605.7)
125.9
(78.2–202.5)
22.2
(11.6–42.8)
2.5
(1.2–5.2)
Herpes zoster 156.9
(74.8–329.1)
58.1
(27.7–121.8)
43.3
(27.6–67.9)
3.2
(1.7–6.2)
Cryptococcal meningitis 227.6
(122.4–422.9)
0 2.2
(0.3–16.0)
0
ART: antiretroviral therapy; CI: confidence interval; OI: opportunistic infection; PYFU: person-years of follow-up
https://doi.org/10.1371/journal.pone.0206796.t002
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We also investigated for risk factors for OI development in patients with a CD4 cell count
>200 cells/μL. In the multivariate model, time-varying viral load (HR: 1.84 per 1 log increase;
95% CI: 1.33–2.54; P<0.001) remained the single predictor of OIs, whereas baseline CD4 cell
count<50 cells/μL as compared to>200 cells/μL (HR: 0.40; 95% CI: 0.20–0.80; P = 0.010) and
time-varying increased hemoglobin level (HR: 0.81 per 1 g/dL; 95% CI: 0.68–0.96; P = 0.015)
were associated with a lower risk of OI development (supporting information, S6 Table).
Discussion
In this urban cohort of 559 patients starting ART in Uganda between April 2004 and April
2005 and followed-up for 10 years the vast majority of OIs (71.4%) occurred in the first year
after ART initiation. Similarly, the incidence rates of overall and individual OIs were highest
in the first year after ART start and decreased with the duration of ART.
This finding, a consequence of the patients’ low immunity at ART initiation, is in-line with
findings from other cohorts in low- and high-income countries [25, 27, 28, 38]. In our cohort,
the median CD4 count of 98 cells/μL (IQR, 21–163 cells/μL) at baseline and the large propor-
tion (88.9%) of patients classified as WHO stage III or IV suggest a high incidence of advanced
disease and immunosuppression at ART initiation. In addition, Immune Reconstitution
Inflammatory Syndrome (IRIS) can contribute to high early incidences of OIs, as restoration
Fig 2. Cumulative probability of acquiring any opportunistic infection by baseline CD4 cell count in a cohort of patients on ART followed up for
10 years. ART: antiretroviral therapy; OI: opportunistic infection.
https://doi.org/10.1371/journal.pone.0206796.g002
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of immune function can cause unmasking of OIs, with mycobacterium tuberculosis being the
most frequent causative agent [39]. However, in a previous publication of this cohort where
mortality causes of the patients were reviewed, the contribution of IRIS to the observed high
early mortality seemed low [40]. Compared to the overall mortality, the number of deaths due
to the incident OI in our cohort was low, most likely because a great proportion of our patients
died in consequence of a prevalent disease.
The most common OIs in this cohort were oral candidiasis, tuberculosis, herpes zoster and
cryptococcal meningitis. This also reflects the most common OIs in sub-Saharan Africa [22].
Table 3. Risk factors for acquiring any opportunistic infection in a cohort of patients on ART followed up for 10 years.
Variable Univariate analysis p Multivariate analysis p
Baseline age
Per 5 years increase 0.88 (0.80–0.97) 0.012 0.94 (0.85–1.04) 0.243
Gender
Male 1.00
Female 1.16 (0.82–1.63) 0.402
Baseline WHO stage
1 or 2 1.00 1.00
3 or 4 2.25 (1.19–4.26) 0.013 1.58 (0.81–3.07) 0.179
Baseline CD4 cell count
>100 cells/μL 1.00 1.00
50–100 cells/μL 1.13 (0.72–1.77) 0.609 0.85 (0.52–1.40) 0.525
<50 cells/μL 1.65 (1.18–2.30) 0.004 0.83 (0.54–1.28) 0.401
Baseline viral load
<5 log copies/μL 1.00
�5 log copies/μL 1.14 (0.78–1.68) 0.502
Baseline regimen
Nevirapine-based 1.00 1.00
Efavirenz-based 0.74 (0.51–1.07) 0.107 0.56 (0.37–0.83) 0.004
Baseline BMI
�18.5 kg/m2 1.00
<18.5 kg/m2 1.09 (0.78–1.52) 0.628
Baseline hemoglobin
>11 g/dL 1.00 1.00
8–11 g/dL 1.62 (1.17–2.23) 0.003 0.95 (0.65–1.38) 0.779
<8 g/dL 2.01 (1.04–3.87) 0.037 1.18 (0.55–2.53) 0.661
Current CD4 cell count
Per 50 cells/μL increase 0.70 (0.64–0.76) <0.001 0.90 (0.81–1.00) 0.050
Current viral load
Per 1 log increase 2.78 (2.41–3.20) <0.001 2.42 (2.05–2.85) <0.001
Current regimen
First-line regimen 1.00
Second-line regimen 1.26 (0.29–5.43) 0.754
Current BMI
Per 1 kg/m2 increase 0.88 (0.83–0.93) <0.001 0.95 (0.90–1.00) 0.071
Current hemoglobin
Per 1 g/dL increase 0.76 (0.70–0.82) <0.001 0.90 (0.81–1.00) 0.045
ART: antiretroviral therapy; BMI: body mass index; WHO: World Health Organization
https://doi.org/10.1371/journal.pone.0206796.t003
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Uganda is among the 20 countries with the highest estimated burden of HIV-tuberculosis co-
infections worldwide, and tuberculosis is the leading cause of death in PLHIV in low-income
countries [41, 42]. This was also reflected in our cohort where tuberculosis was the most fre-
quent AIDS-defining disease with an incidence of 15.3 per 1000 PYFU similarly to other HIV-
cohorts from high tuberculosis burden countries [26, 43–45]. Although tuberculosis can also
occur in PLHIV who are not severely immunocompromised [46], its incidence in our study
decreased with both increased CD4 cell count and the time spent on ART. Compared to high-
income countries, incidences of PJP and esophageal candidiasis were low [28, 47], which could
be explained through limited diagnostic options rather than through lower endemicity. Addi-
tionally, all patients in our cohort were treated with trimethoprim-sulfamethoxazole or dap-
sone prophylaxis regardless of the CD4 cell count.
Unsurprisingly, the cumulative probability and incidence of OI development was signifi-
cantly higher in patients with lower CD4 cell counts at ART start as well as current CD4 cell
counts during follow up. Compared to patients with a current CD4 cell count of 200–349 cells/
μL, the overall incidence of OIs at a current CD4 cell count of 100–200 cells/μL was approxi-
mately 4-fold higher and for those with a CD4 cell count<100 cells/μL over 15-times higher.
This emphasizes the importance of starting ART early in the course of HIV disease by avoiding
severe immunodeficiency and therefore reducing morbidity.
In our cohort, patients started on efavirenz-based regimens had significantly less OIs than
patients on nevirapine-based regimens. A previous publication from this cohort suggests more
favorable virological outcomes in patients started on efavirenz, which potentially reduces the
incidence of OIs [48]. However, our analysis shows that efavirenz may have an independent
effect in decreasing OIs while on ART. Not surprisingly, increased time-varying viral load was
a strong predictor of OIs in our study, which has been demonstrated previously [23, 25, 38, 49,
50]. Reekie et al. [49] reported an almost linear association between viral load and incidences
of AIDS-related events independent of CD4 cell counts. Fenner et al. [51] recently reported
the association between ongoing viral replication and tuberculosis. Uncontrolled HIV replica-
tion may therefore evoke a state of immunosuppression irrespective of CD4 cell counts, as
hypothesized by Ferry et al [52]. A strong protective factor against OIs in our study was
increased time-varying hemoglobin level. Anemia in PLHIV is common and can have several
causes, including drug-induced toxicity (e.g. zidovudine), malnutrition, or through HIV itself
[53, 54], while anemia usually improves with ART [55, 56]. Anemia while on ART is associated
with AIDS, non-AIDS events and death, with the anemia being the result of an underlying pro-
cess, and therefore potentially serving as an indirect marker of disease [57–59].
We performed a separate analysis for risk factors among patients developing OIs with a cur-
rent CD4 cell count>200 cells/μL. Whereas a lower time-varying CD4 cell count was a risk
factor for developing any OI, at a current CD4 cell count >200 cells/μL this effect was not
apparent. Surprisingly, patients with baseline CD4 cell count<50 cells/μL had a significantly
lower risk of developing OIs at a current CD4 cell count >200 cells/μL than patients with a
baseline CD4 cell count>200 cells/μL. We hypothesize that a relevant proportion of our
patients starting with very low CD4 cell counts may have experienced a profound recovery of
their CD4 cell count in response to ART. A larger absolute increase of CD4 cell counts could
therefore result in a lower risk of OI development, which has been demonstrated previously
[60, 61]. However, larger cohort studies are needed to explore our finding further.
With the changing ART guidelines indicating that ART should be started independently of
CD4 cell count (known as the “Test and Start” program), an increase in the number of patients
receiving ART and with higher CD4 cell counts is expected. Therefore, the pattern of OIs
within PLHIV starting ART in today’s resource-limited setting may change compared to our
cohort. However, no increase of CD4 cell counts at ART start was observed in sub-Saharan
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Africa after 2009, when the CD4 threshold for ART eligibility was raised from 200 to 350 cells/
μL [21], and substantial proportions of patients continue to present with advanced disease in
this setting [62].
This study has several strengths and limitations. The strengths of this study are the long fol-
low-up period with a high retention in care, frequent visits on a regular basis and a detailed
standardized questionnaire and clinical examination. These study characteristics resulted in
data collection of high quality. However, as it is common in resource-limited setting, the diag-
nostic options were limited, which may potentially lead to underestimation of overall morbid-
ity and misclassification [63]. OIs that require invasive diagnostic tools may be even more
underestimated than others. For example, esophageal candidiasis may be underdiagnosed due
to lack of endoscopy. In the generic absence of CT-scan, microbiological culture and bron-
choscopy, cases of non-microbiologically confirmed tuberculosis could have been cases of PJP,
atypical mycobacteria or pulmonary forms of Kaposi’s sarcoma, aspergillosis or cryptococco-
sis. In addition, we were unable to include bacterial pneumonias in our analysis due to pre-
dominant presumptive diagnoses and empiric therapy. Also, we failed to collect information
on fluconazole usage as OI prophylaxis, which can affect the incidence of cryptococcal menin-
gitis. Finally, we report an urban cohort in Uganda whose generalizability may be limited due
to the study procedures which included closer monitoring than routine care, for example viral
load measurements within routine care patients on ART at IDI were performed only when
treatment failure was suspected based on clinical criteria or CD4 cell count, which was com-
mon practice up to 2014 [64].
In conclusion, we report high early incidences of OIs which decreased with time on ART
and increase in CD4 cell count in our cohort. Therefore, it is important to start ART early
before impairment of the immune system, which requires expansion of HIV screening services
and immediate linkage to rapid ART, followed by long-term retention. We recommend close
clinical and viral load monitoring, and intensified care of patients newly starting ART or with
advanced disease. Our findings suggest that viral load control should be the foremost objective
for patients on ART while intensified care is required in patients with virological failure or per-
sistent anemia despite ART.
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